Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines
Alexander J Stephens1,2, Nicola A Burgess-Brown2, Shisong Jiang1
1Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
Abstract:
Peptide-based cancer vaccines rely upon the strong activation of the adaptive immune response to elicit its effector function. They have shown to be highly specific and safe, but have yet to prove themselves as an efficacious treatment for cancer in the clinic. This is for a variety of reasons, including tumour heterogeneity, self-tolerance, and immune suppression. Importance has been placed on the overall design of peptide-based cancer vaccines, which have evolved from simple peptide derivatives of a cancer antigen, to complex drugs; incorporating overlapping regions, conjugates, and delivery systems to target and stimulate different components of antigen presenting cells, and to bolster antigen cross-presentation. Peptide-based cancer vaccines are increasingly becoming more personalised to an individual's tumour antigen repertoire and are often combined with existing cancer treatments. This strategy ultimately aids in combating the shortcomings of a more generalised vaccine strategy and provides a comprehensive treatment, taking into consideration cancer cell variability and its ability to avoid immune interrogation.
Insights
Peptide-based cancer vaccines are evolving into complex, personalized treatments. Enhanced vaccine design and combination therapies aim to overcome challenges and improve efficacy against diverse cancers.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Peptide-based cancer vaccines are specific and safe but lack clinical efficacy.
- Tumor heterogeneity, self-tolerance, and immune suppression limit their effectiveness.
- Current challenges necessitate advancements in vaccine design and therapeutic strategies.
Purpose of the Study:
- To explore the evolution of peptide-based cancer vaccine design.
- To discuss strategies for overcoming limitations in current cancer vaccine therapy.
- To highlight the importance of personalized and combination approaches in cancer treatment.
Main Methods:
- Review of current peptide-based cancer vaccine designs.
- Analysis of strategies to enhance antigen presentation and immune response.
- Examination of personalized vaccine approaches and combination therapies.
Main Results:
- Vaccine design has advanced from simple peptides to complex immunomodulatory drugs.
- Incorporation of overlapping regions, conjugates, and delivery systems improves antigen presentation.
- Personalized vaccines tailored to individual tumor antigens show promise.
Conclusions:
- Advanced peptide-based cancer vaccines are becoming more sophisticated.
- Personalization and combination with existing treatments are key to improving efficacy.
- Addressing tumor variability and immune evasion is crucial for successful cancer immunotherapy.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
01:51Vaccinations
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...